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A B S T R A C T
Here we report on seven intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19)-
related acute respiratory distress syndrome (ARDS) who developed positive rectal swabs and invasive
infections due to carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Notwithstanding the
infection prevention measures introduced during the COVID-19 pandemic and changes in the
hospitalised population, attention to CP-Kp infections must remain high, especially in the critically ill
setting.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1. Introduction
Bacterial and fungal infections are common complications of
viral pneumonia, especially in critically-ill patients, as evidenced
during the 2003 severe acute respiratory syndrome coronavirus
(SARS-CoV) epidemic, when Gram-negative bacteria (GNB) and
Candida caused the largest number of secondary infections [1]. It
follows that assessing the risk of difficult-to-treat bacterial
superinfections such as those caused by GNB is crucial in all
suspected cases of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2; 2019 novel coronavirus) infection [2].
Patients with coronavirus disease 2019 (COVID-19) are, in fact,
particularly at risk of developing superinfections, especially those
caused by multidrug-resistant (MDR) pathogens, despite the
improvements in infection control procedures worldwide adopted
during the COVID-19 outbreak, the changes in overall hospital
admissions for other conditions [3], the considerably younger age
and the absence of multiple co-morbidities [4].
Due to the fact that, prior to the COVID-19 outbreak, Italy had an
endemic situation regarding the spread of MDR infections, mainly
due to carbapenemase-producing Klebsiella pneumoniae (CP-Kp)
[5], we evaluated the incidence and time course of CP-Kp infections
during their intensive care unit (ICU) stay in a cohort of ICU
patients affected by COVID-19-related acute respiratory distress
syndrome (ARDS).
2. Materials and methods
From 1 March to 20 May 2020, all COVID-19 patients with ARDS
admitted to the ICU at ‘Città della Salute e della Scienza’ Hospital in
Turin (Italy) were studied. Bloodstream infection (BSI) and
ventilator-associated pneumonia (VAP) were defined according
to the European Centre for Disease Prevention and Control (ECDC).
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-
TOF), Microscan WalkAway plus System (Beckman Coulter, Brea,
CA, USA) and MASTDISCS1 Combi Carba plus disk system (Mast
Group Ltd., Bootle, UK) were used for bacterial identification,
antimicrobial susceptibility testing and to characterise carbape-
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bial Susceptibility Testing (EUCAST) 2019.
3. Results
Among 35 patients, 7 had a positive rectal swab for CP-Kp and
bilateral pulmonary infiltrates (Table 1). Six patients developed
invasive infections and one patient was colonised by CP-Kp during
their ICU stay (two patients were positive for CP-Kp at ICU
admission). Six of the seven patients were transferred from other
hospitals. The median [interquartile range (IQR)] Sequential Organ
Failure Assessment (SOFA) score, Simplified Acute Physiology
Score (SAPS) and Acute Physiology and Chronic Health Evaluation
(APACHE) II score at ICU admission were, respectively, 12 (11–13),
54 (51–60) and 25 (24–26), whilst the median (IQR) MuLBSTA
score [6] was 9 (9–10). The median (IQR) duration of COVID-19
symptoms before hospital admission was 7 (4–7) days, whilst the
median (IQR) duration of ICU stay and mechanical ventilation was
34 (24–40) days and 34 (23–40) days, respectively.
The median (IQR) time between CP-Kp infection and hospital
and ICU admission was 13 (12–19) days and 12 (7–15) days,
respectively. Six patients developed VAP and five had contextual
BSI, in all of five of whom the infection resulted in septic shock with
high vasopressor requirement.
All of the patients received hydroxychloroquine, five of them
received antiviral treatment and four were treated with tocilizu-
mab. Corticosteroids were given in all but one patient (dexameth-
asone 8 mg every 8 h, with variability according to different
hospitals in transferred patients). At ICU admission, 71.4% of
patients had lymphocytopenia. All patients had been previously
treated with broad-spectrum antibiotics (all of them with β-
lactams, five with azithromycin, two with doxycycline and three
with vancomycin), in five cases with a documented prior bacterial
co-infection before CP-Kp, including three VAP and two BSI caused
by Pseudomonas aeruginosa (n = 2), extended-spectrum β-
lactamase (ESBL)-producing K. pneumoniae (n = 1), coagulase-
negative staphylococcus (n = 1) and Enterococcus faecium (n = 1),
respectively. We observed two deaths within 28 days and five
deaths in the ICU in seven patients. Mortality related to CP-Kp
septic shock was 28.6%.
4. Discussion
Few articles are reporting about secondary infections in COVID-
19, but some data confirm that superinfections were identified in
13.5–44% of ICU patients owing to various pathogens, including
MDR-GNB [2].
Known risk factors for the development of CP-Kp infections do
not appear fully applicable in this cohort of patients [4]. In fact, our
population was relatively young and free of significant co-
morbidities, except obesity (57.1%). The reduction in hospital
access for all causes [3], apart from those due to COVID-19, should,
at least theoretically, have contributed to a reduction in the
dissemination of MDR pathogens. Furthermore, infection control
procedures are highly implemented in the context of the COVID-19
pandemic to ensure safety for healthcare workers, maximising
contact precautions.
Conversely, factors potentially implicated in the risk of MDR
infections are increased patient transfer caused by the pandemic
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































39antibiotic treatment before hospital admission, the presence of
other previous invasive bacterial co-infection, and the severity of
the patient cohort requiring venovenous extracorporeal mem-
brane oxygenation (VV-ECMO) support in 71.4% of cases and
continuous renal replacement therapy in 28.6%. In particular, in
patients undergoing ECMO, colonisation by MDR-GNB is frequent9
G. Montrucchio, S. Corcione, G. Sales et al. Journal of Global Antimicrobial Resistance 23 (2020) 398–400and is associated with a more than ten-fold odds for subsequent
infections that are associated with an increased risk of death [7].
Our results appear to suggest the need to keep a major focus on
CP-Kp infections even, and especially, among COVID-19 patients
owing to their extreme fragility, probably linked to immunological
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